JAK2 and early-onset autosomal dominant Alzheimer disease: In 2007, Levine et al. reviewed the role of JAK2 in myeloproliferative disorders, and reported activation of two other major signaling pathways (PI3K/Akt and Ras/Raf/MAPK/ERK) through JAK2 (282), which was later reported by Birzniece et al. (19) as part of growth factor signaling, and Chiba et al. in Alzheimer's disease (20).